Skip to content
Menu

Edesa Biotech Receives European Commission Orphan Designation For Paridiprubart To Treat Acute Respiratory Distress Syndrome

Benzinga Newsdesk 2 hours ago

FDANews

The designation follows a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products, recognizing both the high mortality rates in ARDS and the need for new treatment options for patients.

Orphan drug designation in the European Union provides important regulatory incentives, including reduced development fees, potential market exclusivity following approval, and enhanced development efficiency, which may help streamline clinical development and regulatory interactions. The EMA’s final decision was supported by Phase 2/3 clinical data demonstrating statistically significant improvements in survival among critically ill patients requiring invasive mechanical ventilation. Ten years is the baseline length of exclusivity under existing EU law, with potential for extensions and reductions. A new EU orphan drug exclusivity scheme will take effect in 2028. Paridiprubart has been entered into the Community Register of Orphan Medicinal Products under designation number EU/3/26/3320.

Read at benzinga.com